Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
NYSE MKT:PLX
Protalix (PLX) Stock Price & Analysis
642 Followers
PLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.94 - $2.21
Previous Close$2.03
Volume581.43K
Average Volume (3M)972.57K
Market Cap
$116.48M
Enterprise Value$127.78M
Total Cash (Recent Filing)$22.18M
Total Debt (Recent Filing)$33.47M
Price to Earnings (P/E)-6.6
Beta-0.61
Next Earnings
May 10, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding50,665,598
10 Day Avg. Volume432,583
30 Day Avg. Volume972,571
Standard Deviation0.21
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-6.86
Price to Sales (P/S)2.03
Price to Cash Flow (P/CF)5.00
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit4.56
Enterprise Value/Ebitda-11.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Protalix News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $0.94 and its highest was $2.21 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Currently, no data Available
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is May 10, 2023 which is in 51 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Feb 27, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.07.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 57,380,980 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 2.747%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Among the largest hedge funds holding Protalix Biotherapeutics’s share is Highbridge Capital Management LLC. It holds Protalix Biotherapeutics’s shares valued at 3M.
---
Protalix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PLX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $155.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.7%
Last 30 Days ▲ 16.9%
Last 30 Days ▲ 16.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protalix Biotherapeutics
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.
---
---